Research programme: immunoproteasome inhibitors - IpiNovyx Bio
Latest Information Update: 08 Oct 2021
At a glance
- Originator Cornell University; Tri-Institutional Therapeutics Discovery Institute
- Developer IpiNovyx Bio
- Class Small molecules
- Mechanism of Action Immunomodulators; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 06 Oct 2021 IpiNovyx Bio in-licenses the technology for immunoproteasome inhibitors from Cornell University
- 06 Oct 2021 Preclinical trials in Autoimmune disorders in USA (unspecified route) prior to October 2021
- 06 Oct 2021 Preclinical trials in Inflammation in USA (unspecified route) prior to October 2021